Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by BMO Capital Markets
BMO Capital Markets reiterated their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) in a research report released on Tuesday morning, Benzinga reports. They currently have a $1,300.00 price objective on the biopharmaceutical company’s stock. Several other analysts have also weighed in on REGN. TD Cowen upped their price objective on Regeneron […]
27 Sep 07:58 · The Cerbat Gem